NervGen Pharma Corp.
NGENF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $211 | $145 | $85 | $106 |
| - Cash | $17 | $12 | $22 | $17 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $194 | $134 | $63 | $89 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$25 | -$18 | -$23 | -$13 |
| % Margin | – | – | – | – |
| Net Income | -$24 | -$22 | -$21 | -$13 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.36 | -0.38 | -0.39 | -0.32 |
| % Growth | 5.3% | 2.6% | -21.9% | – |
| Operating Cash Flow | -$17 | -$11 | -$18 | -$8 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$17 | -$11 | -$18 | -$8 |